コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 + mood-stabilizer) or monotherapy (placebo + mood-stabilizer).
2 agonists, atomoxetine, antidepressants, and mood stabilizers).
3 thium fulfilled the a priori definition of a mood stabilizer.
4 oate (2-propylpentanoate) is a commonly used mood stabilizer.
5 which if any agents meet this definition of mood stabilizer.
6 four roles included in their definition of a mood stabilizer.
7 ssants was common, often in the absence of a mood stabilizer.
8 r disorder did not include prescription of a mood stabilizer.
9 [2.6] years) who initiated an anticonvulsant mood stabilizer.
10 with an antidepressant in conjunction with a mood stabilizer.
11 iving an antidepressant while treated with a mood stabilizer.
12 and those receiving an antidepressant plus a mood stabilizer.
13 Valproate (VPA) is a commonly prescribed mood stabilizer.
14 rupt/rapid versus gradual discontinuation of mood stabilizer.
15 ertraline, or venlafaxine as an adjunct to a mood stabilizer.
16 th therapeutic effects and were specific for mood stabilizers.
17 isorder is a useful tool in conjunction with mood stabilizers.
18 pathway may mediate the antimanic effects of mood stabilizers.
19 raging results when used in conjunction with mood stabilizers.
20 ents with mood disorders who were prescribed mood stabilizers.
21 red combinations of established and putative mood stabilizers.
22 rolled studies of the use of combinations of mood stabilizers.
23 inhibitors, memantine, antidepressants, and mood stabilizers.
24 56 (20.5%) SUD medications, and 1706 (12.2%) mood stabilizers.
25 s weight gain than commonly used alternative mood stabilizers.
26 ics in large measure supplanting traditional mood stabilizers.
27 sychoactive drugs such as antipsychotics and mood stabilizers.
28 benefits with antidepressants combined with mood stabilizers.
29 nt role in the actions of antispychotics and mood stabilizers.
30 ith ineffective regimens that do not include mood stabilizers.
31 tion of paliperidone and these two classical mood stabilizers.
32 wer antipsychotics with those of traditional mood stabilizers.
33 validated with several clinically effective mood stabilizers.
34 ated pathway and Bcl-2 are major targets for mood stabilizers.
35 and as a therapeutically relevant target for mood stabilizers.
37 antidepressant medications (14.4% to 48.6%), mood stabilizers (5.3% to 14.5%), stimulants (1.9% to 6.
39 vents provides a potential mechanism whereby mood stabilizers alleviate cerebral morphometric deficit
40 mood stabilizer was more efficacious than a mood stabilizer alone, and as efficacious as haloperidol
41 time to recovery relative to treatment with mood stabilizers alone, and treatment with antidepressan
44 ave themselves been reported to be effective mood stabilizers, although the importance of increased c
45 ve recently reported that the anticonvulsant mood stabilizers (AMS), valproic acid, carbamazepine, an
46 Treatments and were currently treated with a mood stabilizer, an atypical antipsychotic, or their com
48 21 is a key mediator of the effects of these mood stabilizers and a potential new therapeutic target
50 curring psychiatric conditions, or receiving mood stabilizers and antipsychotics were not included.
51 some pharmacological treatments - primarily mood stabilizers and atypical antipsychotics - augmented
52 sts that pharmacological interventions using mood stabilizers and atypical antipsychotics may be effe
54 K-3beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the desig
58 cs, antidepressants, anxiolytics, hypnotics, mood stabilizers, and medications for attention-deficit/
59 otropic medications such as antidepressants, mood stabilizers, antianxiety drugs and opioid antagonis
60 ons can be induced by valproic acid (VPA), a mood-stabilizer, anticonvulsant and histone deacetylase
61 for attention-deficit/hyperactive disorder, mood stabilizers, antidepressants, benzodiazepines and r
62 and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opio
63 0 to investigate which antipsychotics and/or mood stabilizers are better for patients with bipolar di
68 ntipsychotic drugs (APD)s and anticonvulsant mood-stabilizers are now frequently used in combination
69 e whether zonisamide, another anticonvulsant mood stabilizer, as well as lithium, a mood stabilizer w
70 subjects with BD taking vs those not taking mood stabilizers, as well as in the left optic radiation
71 Despite important advances in the range of mood stabilizers available, the pharmacological treatmen
72 was partially (atypical APDs) or completely (mood-stabilizers) blocked by the serotonin (5-HT)1A rece
73 only the relative risks of fetal exposure to mood stabilizers but also the high risk of recurrence an
75 e found marginal efficacy for amantadine and mood stabilizers, but found no increased family history
76 tonin reuptake inhibitors, by 98% for use of mood stabilizers, by 171% for use of antipsychotics, and
77 tonin reuptake inhibitors, by 63% for use of mood stabilizers, by 60% for use of antipsychotics, and
78 te initiation in bipolar patients not taking mood stabilizers, careful assessment to rule out bipolar
81 up by querying the effect of treatment with mood stabilizers commonly prescribed in bipolar disorder
86 y and are known targets of the anti-suicidal mood stabilizer drug lithium, which increases their expr
89 disorder and the consequences of the use of mood stabilizers during pregnancy, and a consensus docum
95 s, the authors examined trends in the use of mood stabilizers, first- and second-generation antipsych
96 mary psychiatric diagnosis, were receiving a mood stabilizer for 4 or more weeks, and had a Montgomer
98 Lithium salts are commonly prescribed as a mood stabilizer for individuals with bipolar disorder.
100 d current substance dependence, treated with mood stabilizers for >or=2 weeks, were randomly assigned
102 cardiovascular disorders, arthritis, and as mood stabilizers for bipolar disorder; however, the mech
103 nd that lithium and valproate, commonly used mood stabilizers for the treatment of manic-depressive i
104 ne, and as efficacious as haloperidol plus a mood stabilizer, for the rapid control of manic symptoms
107 sychotics (HR, 0.45 [95% CI, 0.23-0.88]) and mood stabilizers (HR, 0.64 [95% CI, 0.46-0.90]) were ass
108 definition by which an agent is considered a mood stabilizer if it has efficacy in treating acute man
113 ent and pattern of blood serum monitoring of mood stabilizers in Medicaid patients with bipolar disor
115 nical synergism of an APD and anticonvulsant mood-stabilizer in improving the cognitive deficits pres
117 Prescription of an antidepressant without a mood stabilizer increased substantially, from 17.9% in t
118 es despite the prescription of commonly used mood stabilizers, into a CT group or control group.
122 3beta (GSK3beta) inhibitors, especially the mood stabilizer lithium chloride, are also used as neuro
123 to account for the behavioral actions of the mood stabilizer lithium in various animal models of mood
126 ctions of the structurally highly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-
127 citotoxicity, and that co-treatment with the mood stabilizers lithium and valproic acid (VPA) induces
128 urrent manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, ris
129 a typical antipsychotic (perphenazine) and a mood stabilizer (lithium, carbamazepine, or valproate),
130 lar disorder, or psychosis or treatment with mood stabilizer (lithium, valproate, or carbamazepine),
131 relationship of adherence to treatment with mood stabilizers (lithium, carbamazepine, and sodium val
133 tidepressant treatment in combination with a mood stabilizer may be warranted in some patients with b
134 bits glucocorticoid activation suggests that mood stabilizers may counteract the deleterious effects
135 2%]; 20.3% decrease), with antipsychotic and mood stabilizer medication prescription fills (216 468 [
137 o have used antianxiety, antidepressant, and mood stabilizer medications, and those with borderline o
139 of and the response to antidepressants (AD), mood stabilizers (MS), and antipsychotics (AP) in the tr
140 Treatment with antidepressants (AD) in MD, mood-stabilizers (MS) in BD, and antipsychotics (AP) in
141 ng older patients with bipolar disorder with mood stabilizers need evidence from age-specific randomi
142 Among patients treated with a concurrent mood stabilizer, no acute change in risk of mania was ob
145 ributable to treatment with antidepressants, mood stabilizers or electroconvulsive therapy (ECT).
146 andomized to receive cotherapy (olanzapine + mood-stabilizer) or monotherapy (placebo + mood-stabiliz
147 Because antipsychotic drugs are used as mood stabilizers our studies focused on a newly-marketed
150 plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under condition
151 -two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy h
152 o receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy o
153 ficant trends favoring the group receiving a mood stabilizer plus placebo were observed across the se
155 administration of lithium, a clinically used mood stabilizer, promoted the proliferation of neuronal
156 addition of an antidepressant to an ongoing mood stabilizer regimen were followed prospectively for
157 idepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have
158 Although the underlying mechanism(s) of this mood stabilizer remains controversial, recent evidence l
162 view will focus on four molecular targets of mood stabilizers that are known to play integral roles i
164 der (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more
166 (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in You
167 -blind treatment in which in addition to the mood stabilizer they received either continued perphenaz
171 ts were euthymic at conception and continued mood stabilizer treatment or discontinued treatment prox
172 mong women who discontinued versus continued mood stabilizer treatment, recurrence risk was twofold g
181 In contrast, behaviorally effective chronic mood stabilizer treatments in mice inhibit GSK3beta and
185 ntial clinical utility of the anticonvulsant mood stabilizer, valproate, in bipolar disorder with co-
186 d risperidone, as well as the anticonvulsant mood-stabilizers, valproic acid (VPA), zonisamide, and c
187 ider the relative risks of fetal exposure to mood stabilizers versus the high recurrence risks after
189 0.62; 95% CI, 0.45-0.86), whereas the use of mood stabilizers was associated with increased odds of i
190 The treatment recommendation for adjunctive mood stabilizers was the only recommendation for which c
191 sant medication, as compared with the use of mood stabilizers, was not associated with increased effi
193 Thus, pharmacological interventions such as mood stabilizers, which dampen limbic irritability, or s
194 ession that was inadequately responsive to a mood stabilizer with or without concomitant antidepressa
196 ia (OR, 6.75; 99% CI, 3.52-12.92); 2 or more mood stabilizers, with bipolar disorder (OR, 15.46; 99%
197 antipsychotics, anxiolytics, hypnotics, and mood-stabilizers, with statins as a negative control out
198 lsant mood stabilizer, as well as lithium, a mood stabilizer without anticonvulsant properties, also